Skip to main content
Premium Trial:

Request an Annual Quote

Progenika's Chip-Based Lipoprotein Lipase Deficiency Test Obtains CE Mark


By Justin Petrone

Progenika Biopharma this week said that it has received a CE mark for its LPLchip, enabling it to sell the array to physicians in the European Union to help diagnose patients with complete or partial lipoprotein lipase deficiency.

The LPLchip is one of several diagnostic arrays that Bilbao, Spain-based Progenika has developed. The low-density chip allows users to detect more than 120 mutations in the LPL gene, supports the diagnosis of LPLD, and can be used to identify patients who may benefit from gene therapy for LPLD, according to the firm.

Indeed, the LPLchip was designed with Amsterdam Molecular Therapeutics, a Dutch firm that has developed a new genetic treatment for LPLD called Glybera. According to Progenika, AMT filed Glybera for marketing authorization with the European Medicines Agency earlier this year, and a decision on the approval is expected by the middle of 2011. Progenika began working with AMT last year (BAN 11/3/2009).

Additionally, Progenika said the LPLchip can be used to identify patients at elevated risk for familial combined hyperlipidemia and premature atherosclerosis due to the presence of non-compound heterozygous LPL mutations.

Familial lipoprotein lipase deficiency disrupts the normal breakdown of fats in the body, characterized by inflammation of the pancreas, abdominal pain, enlargement of the liver and spleen, and small yellow skin lesions called eruptive xanthomas, according to the US National Institutes of Health.

The NIH estimates that the condition affects about 1 person per million worldwide, though it states that it is "much more common" in some areas of Quebec.

AMT is currently following up study on two clinical studies conducted in Europe and Canada, and is conducting a third clinical study in Canada. In these three studies, Glybera has led to a "sizeable decrease in the incidence of pancreatitis," Progenika said.

In addition to the LPLchip, Progenika also sells its Lipochip for the diagnosis of familial hypercholesterolaemia, and its Bloodchip for ensuring compatibility in blood transfusions. Both of those arrays are available for research use only in the US, where the company maintains an office in Cambridge, Mass.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.